Indefinite Delivery Contract SPE2DR25D9143

The Indefinite Delivery Contract (IDC) SPE2DR25D9143 was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The IDC, valued at $4,999,999, has an ultimate completion date of December 31, 2036 and covers the delivery of a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide.

This IDC was issued under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) procurement, which aims to establish multiple prime vendor contracts to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency, the U.S. Coast Guard, and U.S. Naval Fleet. The procurement is a firm-fixed price, requirements-type contract with a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion. Awards will be made on a regional basis, with at least three different contractors selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items, to ensure resiliency and access to vital pharmaceuticals during contingencies or natural disasters.